The Right Stock At The Right Time®  Launch Smart Chart
Updated For:
Daily Market Comment 
Dr. ME Talks Stocks 
Market Letter
On The Edge
The Outlook
Email Alert

News & Analysis
Stocks & Funds
Options & Futures
Personal Finance

By Providers
S&P Capital IQ


10/20/16 04:00:24 PM

Omeros Corporation, Tyson Foods, Inc., AutoZone, Inc.

Omeros Corporation(OMER) : Cantor Fitzgerald analysts maintain their Buy rating on Omeros Corporation (NASDAQ: OMER) after promising OMS721 data in kidney disorders and associated improvement of thrombotic microangiopathies (TMA) blood markers. Following promising OMS721 data in kidney disorders, Omeros added that the drug improved TMA blood markers in 3/5 hematopoietic stem cell transplantation (HSCT) patients. Related Link: Omeros Finds Buyers In The $7 Handle Again "Platelet count and haptoglobin levels were increased, while mean LDH levels have decreased from baseline. These results were as robust as those reported last year from two aHUS patients, lending confidence to the assumption of broad utility of OMS721 in TMAs," analyst Elemer Piros wrote in a note. As such, Omeros could pursue three distinct indications with OMS721 in pivotal trials beginning in the fourth quarter. Piros expects the company's deep pipeline to deliver steady news flow over the next 12-24 months. At time of writing, shares of Omeros rose 5.89 percent to $8.06. Piros has a price target of $21.

Tyson Foods, Inc.(TSN) : Shares of Tyson Foods, Inc. (NYSE: TSN) lost about 8.9 percent of their value on October 7, after Pivotal Research downgraded the stock to Sell, issuing a price target of $40, which implied tremendous downside from the stock's price above $74. At that time, the Vetr crowd also rated the stock a Sell (2.5 Stars). Related Link: Here's How Crowdsourced Ratings Can Beat The Market However, the stock has managed to recuperate, rebounding more than 3 percent since October 10. This seems to have led the Vetr crowd to upgrade the stock on Thursday, from 2.5 Stars (Sell) to 3.0 Stars (Hold) - out of a possible 5 Stars rating. However, it should be noted that, while 60 percent of the crowd's ratings are bullish at the time, its average price target of $68.87 implies a downside potential of more than 1.5 percent.

AutoZone, Inc.(AZO) : Argus maintained its Buy rating on AutoZone, Inc. (NYSE: AZO) as it believes the company is poised to benefit from aging car population, low gas prices and increasing miles driven per car. "The average age of an American car is over 11 years and there are a growing number of cars that are more than seven years old. If vehicles are driven approximately 12,500 miles per year, a car would have 87,500 miles after seven years," analyst Christopher Graja wrote in a note. The analyst noted these stats suggest increasing number of cars out of warranty, requiring extra maintenance, while low gas prices should encourage drivers to put more miles on their old vehicles. In FY 2016, Graja expects the company to focus on improving inventory availability to drive sales and offer a wider assortment of parts through its programs. "The auto parts sector is relatively insulated from internet competition because of in-store service, relationships with parts suppliers and established delivery to commercial customers, but we expect AZO to improve its own online offering," Graja highlighted. However, the analyst cut his FY17 EPS estimate to $45.75 from $46.00 to reflect higher expense rate. The current consensus estimate is $45.46.


Past performance is not a guarantee of future results. The data contained in Market Edge is obtained from sources considered by Computrade Systems, Inc. to be reliable but the accuracy and completeness thereof are not guaranteed. Computrade Systems, Inc. does not and will not warrant the performance and results that may be obtained while using the Market Edge research service.
The Market Edge research service & Second Opinion are neither offers to sell nor solicitations of offers to buy any security.
Company profile, estimates and financials provided by S&P Capital IQ
See User Agreement for other disclaimers.
Market Edge and Second Opinion are registered trademarks of Computrade Systems, Inc.
© 2016 Computrade Systems, Inc.
© 2016 The McGraw-Hill Companies, Inc. S&P Capital IQ is a division of The McGraw-Hill Companies, Inc. See full Copyright for details.